Mesoblast is developing biotherapeutics based on its proprietary cell-based technologies. The Company’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs.
Mesoblast’s cell-based core technologies include its Mesenchymal Precursor Cell (MPC) technology platform, currently used to develop products derived from bone marrow and adipose tissue sources, its Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs). In addition, Mesoblast is developing certain biotherapeutics based on protein factors derived from its proprietary cellular platforms.
Mesoblast’s lead clinical products are derived from its MPCs, extremely rare cells found around blood vessels in various tissues, and characterized by specific surface markers, which facilitates their extraction and purification by immunoselection. MPCs give rise to all culture-expanded multi-potential fibroblastoid colony forming units (CFU-F) which typically characterize cultured mesenchymal stem cells. These observations suggest that MPCs are the in vivo precursors of all the mesenchymal-lineage stem cells in the adult.
MPCs can differentiate into bone, fat and cartilage. Additionally, these cells release a series of factors which can act on target tissues to induce blood vessel formation, prevent heart muscle death, reduce fibrous scar tissue, improve bone and cartilage growth, and modulate the key elements of the immune system, including monocytes and T cells.
Mesoblast’s intellectual property (IP) covers the Company’s allogeneic (‘off-the-shelf’) products which are developed using highly efficient extraction, purification and scale-up processes. Together, Mesoblast’s IP and state-of-the-art manufacturing processes facilitate the Company’s commercial model to develop cost-effective biotherapeutics across multiple clinical indications.
The Company’s MPC products are currently being evaluated in patients with congestive heart failure, acute myocardial infarction, type 2 diabetes and kidney disease, rheumatoid arthritis, inflammatory lung diseases and intervertebral disc disease. For more information, please visit Products.
Mesoblast's approach to product development has been to ensure rigorous science is performed using purified cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies are used to appropriately guide clinical trials. Using well defined purified cell populations has also facilitated a proprietary manufacturing process that ensures reproducibility and batch to batch consistency. Our manufacturing, translational, and clinical activities meet stringent criteria set by regulatory agencies in each jurisdiction the Company operates.
Mesoblast is partnered with Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPC products in a number of fields, including cardiovascular diseases and neurologic conditions.
Mesoblast has established an alliance with Lonza Group for the clinical and long-term commercial manufacturing of its allogeneic MPC products. For more information, please visit Partnerships.